http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018265520-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42bafb880871970d57dea45639fd1019 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2018-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8024013c0e6750f5131edea54cffa119 |
| publicationDate | 2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2018265520-A1 |
| titleOfInvention | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same |
| abstract | The present invention provides a compound of Formula I: n n n n n n n n n n wherein R is H, a methyl group, an ethyl group, a n-propyl group, an iso-propyl group, or a n-butyl group; and R 1 is H, a 4′-methyl group, a 4′-OH, a 4′-OMe group, a 2′,3′-C 2 H 4 group, a 3′,4′-C 2 H 4 group, a 3′,4′-diF, a 3′,4′,5′-triF, or a 4′-OCF 3 ; and optionally including a salt or a hydrate of said compound, and further provides a pharmaceutical composition comprising the compound of Formula I and one or more acceptable pharmaceutical carriers. A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutical composition comprising a compound of Formula I and one or more acceptable pharmaceutical carriers to the patient is disclosed. |
| priorityDate | 2015-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 944.